Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Fluorouracil. Found 27 abstracts

no pagination
Boland PM, Meyer JE, Berger AC, Cohen SJ, Neuman T, Cooper HS, Olszanski AJ, Davey M, Cheng JD, Lebenthal A, Burtness BA, Scott WJ, Astsaturov IA. Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. Am J Clin Oncol. 2017 Aug;40(4):393-8.   PMCID: PMC5026539
Li D, Moughan J, Crane C, Hoffman JP, Regine WF, Abrams RA, Safran H, Liu C, Chang P, Freedman GM, Winter KA, Guha C, Abbruzzese JL. RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704. Int J Radiat Oncol Biol Phys. 2016 Mar;94(3):554-60.   PMCID: PMC4876948
Zhao S, Tang H, Yan D, Fan J, Sun H, Wen Y, Yu F, Cui F, Zhang D, Xue Y, Liu C, Yue B, Chen J, Wang J, Wang X, Zhang M, Yu Y, Jiang W, Liu X, Mi Y, Zhou Z, Qin X, Peng Z. DDA1 promotes stage IIB-IIC colon cancer progression by activating NFkappaB/CSN2/GSK-3beta signaling. Oncotarget. 2016 Apr 12;7(15):19794-812.   PMCID: PMC4991419
Marks EI, Tan C, Zhang J, Zhou L, Yang Z, Scicchitano A, El-Deiry WS. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. Cancer Biol Ther. 2015 Jan;16(12):1710-9.   PMCID: PMC4847811
Marks EI, Brennan M, El-Deiry WS. Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma. Cancer Biology & Therapy. 2015 Aug;16(8):1136-9.   PMCID: 4622690
Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG. Efficacy Endpoints of Radiation Therapy Group Protocol 0247: A Randomized, Phase 2 Study of Neoadjuvant Radiation Therapy Plus Concurrent Capecitabine and Irinotecan or Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer. International Journal of Radiation Oncology Biology Physics. 2015 Jan;91(1):116-23.   PMCID: 4385459
Dotan E, Meropol NJ, Burtness B, Denlinger CS, Lee J, Mintzer D, Zhu F, Ruth K, Tuttle H, Sylvester J, Cohen SJ. A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. J Gastrointest Cancer. 2012 Dec;43(4):562-9.   PMCID: 3400721
Konski A, Li T, Sigurdson E, Cohen SJ, Small W, Spies S, Yu JQ, Wahl A, Stryker S, Meropol NJ. Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation. Int J Radiat Oncol Biol Phys. 2009 May;74(1):55-9.   PMCID: PMC2933375
Konski A, Garcia M, John M, Krieg R, Pinover W, Myerson R, Willett C. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. Int J Radiat Oncol Biol Phys. 2008 Sep;72(1):114-8.   PMCID: PMC2570743
Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.[see comment]. Journal of Clinical Oncology. 2006 Sep;24(25):4069-77.
Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ, National Comprehensive Cancer N. Rectal cancer clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2005 Jul;3(4):492-508.
Brown TA, Ridge JA, Goldberg M. Gastrostomy-site tumor recurrence is not always fatal. Surgical endoscopy. 2003 Feb;17(2):351.
Sasson AR, Wetherington RW, Hoffman JP, Ross EA, Cooper H, Meropol NJ, Freedman G, Pingpank JF, Eisenberg BL. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. International Journal of Gastrointestinal Cancer. 2003 Jan;34(2-3):121-8.
Marsh JC, Catalano P, Huang J, Graham DL, Cornfeld MJ, O'Dwyer PJ, Benson AB. Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer. Clin Colorectal Cancer. 2002 May;2(1):43-50.
Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, Pfister D, Sherman E, Goberdhan A, Hoffman RM, Shah J. Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head & neck. 2002 May;24(5):437-42.
Takahashi N, Li W, Banerjee D, Guan Y, Wada-Takahashi Y, Brennan MF, Chou TC, Scotto KW, Bertino JR. Sequence-dependent synergistic cytotoxicity of ET-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res. 2002 Dec;62(23):6909-15.
Cianfrocca M, Goldstein LJ. Operable breast cancer. Current treatment options in oncology. 2001 Apr;2(2):157-67.
Meropol NJ, Niedzwiecki D, Hollis D, Schilsky RL, Mayer RJ. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. Cancer. 2001 Apr;91(7):1256-63.
O'Dwyer PJ, Manola J, Valone FH, Ryan LM, Hines JD, Wadler S, Haller DG, Arbuck SG, Weiner LM, Mayer RJ, Benson AB. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J Clin Oncol. 2001 May;19(9):2413-21.
Pingpank JF, Hoffman JP, Ross EA, Cooper HS, Meropol NJ, Freedman G, Pinover WH, LeVoyer TE, Sasson AR, Eisenberg BL. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg. 2001 Mar;5(2):121-30.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Fluorouracil

Fluorouracil Antineoplastic Combined Chemotherapy Protocols Male therapeutic use Female administration & dosage Aged drug therapy Middle Aged pathology mortality Adult Human Adenocarcinoma 80 and over Aged Deoxycytidine Colorectal Neoplasms Survival Analysis adverse effects analogs & derivatives therapy Middle Age Leucovorin Treatment Outcome Disease-Free Survival Neoadjuvant Therapy Rectal Neoplasms Mitomycin US Gov't Support-PHS Camptothecin radiotherapy Organoplatinum Compounds metabolism surgery Adjuvant Radiotherapy drug effects methods Oral Administration dt [Drug Therapy] Antineoplastic Antimetabolites Antineoplastic Agents Cisplatin aa [Analogs & Derivatives] Neoplasm Staging 51-21-8 (Fluorouracil) Drug Administration Schedule Nude Mice Enzyme Inhibitors Breast Neoplasms ad [Administration & Dosage] tu [Therapeutic Use] Retrospective Studies Local Neoplasm Recurrence Disease Progression metastatic colorectal adenocarcinoma Neoplastic Gene Expression Regulation su [Surgery] secondary Thymidylate Synthase Uracil 0 (Antineoplastic Combined Chemotherapy Protocols) Chemoradiotherapy Lung Neoplasms Tumor Cell Line Positron-Emission Tomography genetics pa [Pathology] Doxorubicin Squamous Cell Carcinoma Pancreatic Neoplasms Liver Neoplasms dosage rt [Radiotherapy] Biopsy Tumor Biomarkers 951-77-9 (Deoxycytidine) pharmacology 7689-03-4 (Camptothecin) derivatives Prognosis Paclitaxel P-Glycoprotein Nonparametric Statistics capecitabine Pancreatectomy Immunohistochemistry Capecitabine Salvage Therapy Proportional Hazards Models Piperidines Interferon Alfa-2a 50-07-7 (Mitomycin) Fibrosis et [Etiology] DNA-Binding Proteins Reverse Transcriptase Polymerase Chain Reaction biosynthesis Analysis of Variance adverse Feasibility Studies EC 1-3-1-2 (Dihydrouracil Dehydrogenase (NADP)) Radiotherapy Dosage Inhibitory Concentration 50 Colonic Neoplasms Genetic Polymorphism Cell Survival Practice Guidelines Thymidine Phosphorylase effects Quinazolines Heterologous Transplantation Methotrexate Cultured Tumor Cells Predictive Value of Tests Stomach Neoplasms 154361-50-9 (capecitabine) Thiazoles Retreatment Phosphonoacetic Acid Fluorodeoxyglucose F18 5-fu Mouth Neoplasms regorafenib Postoperative Period Carcinoembryonic Antigen administration & Case Report Effects] Isoquinolines diagnosis di [Diagnosis] 58-05-9 (Leucovorin) Carboplatin analogs & Adjuvant Chemotherapy Non-US Gov't Support tumor marker ae [Adverse COP9 Signalosome Complex HT29 Cells NFkappaB Molecular Targeted Therapy Aspartic Acid Monoclonal Antibodies-Humanized tumor recurrence Drug Synergism pharmacokinetics RecQ Helicases Pancreaticoduodenectomy
Last updated on Friday, January 03, 2020